Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo's top US exec wants more insurance coverage for weight-loss drugs
Denmark's Novo Nordisk , the maker of weight-loss drug Wegovy, hopes insurance will cover more U.S. users of the medication and balance direct-to-consumer sales that have driven the fast-growing market, the company's top U.S. executive said.
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
Novo Nordisk stock rises 6% after the launch of a EUR 60.2M foundation-backed initiative to speed cardiometabolic drug discovery and support Europe-wide innovation.
Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying
Novo Nordisk is upgraded to a 'Strong Buy' after a weak Q1 and significant stock price decline, presenting a compelling long-term entry point. NVO's GLP-1 portfolio, including Wegovy and Ozempic, faces near-term pricing headwinds but benefits from long-term tailwinds despite the upcoming 2027 price cuts. Strategic investments, aggressive R&D, and the Akero acquisition position NVO for the next stage of differentiation as the obesity market expands toward major opportunity.
Novo Nordisk's Wegovy pill headlines mask complicated competitive reality
Novo Nordisk's (NYSE:NVO) Wegovy pill is running three times ahead of rival Zepbound at the equivalent stage of launch, according to pharmacy data, a headline that implies dominant market positioning in oral GLP-1 therapeutics. But the data supporting that claim comes with substantial qualifications that tell a different story.
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.
Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion
A cyber extortion group claimed on Tuesday to have stolen more than a terabyte of data from pharmaceutical giant Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully demanding $25 million from the company.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk: I Was Fooled By The Market Again (Rating Upgrade)
Novo Nordisk has significantly regained the market's confidence as the Wegovy pill drives notable recovery and market share stabilization. NVO's international operations offset U.S. pricing pressures, with oral GLP-1 demand proving additive rather than cannibalistic to injectables. Despite a projected 7% sales decline in 2024, NVO maintains robust 41%+ operating margins and trades at historically low 14.1x earnings.
Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO
Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill "very soon," CEO Mike Doustdar said Tuesday, in a move to catch up with rival Eli Lilly in the world's second-largest pharmaceutical market.
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
